4Lahuerta J J, Grande C, Martinez - Lopez J, et al. Tandem transplants with different high - dose regimens improve the complete remission rates in multiple myeloma. Results of a grupo espanol desindromes linfoproliferativos/trasplante autologo de medula osea phase Ⅱ trial [J]. Br J Haematol, 2003, 120: 296-303.
5Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma [ J ]. N Engl J Med, 2003, 349:2495 - 2502.
6Einsele H, Schafer HJ, Hebart H, et al. Follow - up of patients with progressive multiple myeloma undergoing allografts after reduced - intensity conditioning [J]. Br J Haematol, 2003, 121:411 -418.
7Barlogie B, Shaughnessy J, Zangari M, et al. High - dose therapy and irmnunomodulatory drugs in multiple myeloma [ J], Semin Oncol, 2002, 29 (Suppl 17) : 26 - 33.
8Alexanian R, Weber D, Dimopoulos M, et al. Randomized trial of alpha - interferon or dexamethasone as maintenance treatment for multipie myeloma [J]. Am J Hematol, 2000, 65: 204-209.
9Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al. Interferonalpha as maintenance therapy in patients with multiple myeloma [J]. Ann Oncol, 2005, 16: 634-639.
10Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate - day prednisone improves survival in multiple myeloma patients [J]. Blood, 2002, 99:3163-3168.
2Hatzimichael E, Dasoula A, 8enetatos L, et aL Study of specific genetic and epigenetic variables in multiple myeloma[J]. Leuk Lymphoma, 201 0, 51 (1 2):2270-2274.
3Rossi M, Di Martino MT, Morelli E, etal. Molecular targets for the treatment of multiple myeloma[J]. Curt Cancer Drug Targets, 2012, 12(7):757-767.
4Tassone P, Neri P, Burger R, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma[J]. Curr Cancer Drug Targets, 2012, 12(7):814-822.
5Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies[J]. Int J Hematol, 2011,94(4):344-354.
6Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiplemyeloma 2011[J]. BrJ Haematol, 2011, 154(1):32-75.
7Hasskarl J, Ihorst G, De Pasquale D, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma[J]. Leuk Lymphoma, 2011, 52(2):247-259.
8Pathak AB, Advani SH, Gopal R, et al. Urinary bladder cancer following cyclophosphamide therapy for Hodgkin's disease[J]. Leuk Lymphoma, 1992, 8(6):503-504.
9Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study[J]. Eur J Haernatol, 2000, 65(2):123-127.
10Razavi P, Rand KA, Cozen W, et al. Patterns of second primary malignancy risk in multiplemyelomapatients before and after the introduction of novel therapeutics[J]. Blood Cancer J, 2013, 3(7):121-126.
